Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 17

1.

HIV resistance to reverse transcriptase inhibitors.

De Clercq E.

Biochem Pharmacol. 1994 Jan 20;47(2):155-69. Review. No abstract available.

PMID:
7508227
2.

Specific HIV-1 reverse transcriptase inhibitors.

Debyser Z, Pauwels R, Andries K, De Clercq E.

J Enzyme Inhib. 1992;6(1):47-53. Review. No abstract available.

PMID:
1285302
3.

The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.

Emini EA, Byrnes VW, Condra JH, Schleif WA, Sardana VV.

Arch Virol Suppl. 1994;9:11-7. Review.

PMID:
7518271
4.

A novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.

Merluzzi VJ, Rosenthal AS.

Adv Exp Med Biol. 1992;312:89-94. Review. No abstract available.

PMID:
1381140
5.

TIBO derivatives: a new class of highly potent and specific inhibitors of HIV-1 replication.

Pauwels R, Andries K, Debyser Z, Kukla M, Schols D, Desmyter J, De Clercq E, Janssen PA.

Biochem Soc Trans. 1992 May;20(2):509-12. Review. No abstract available.

PMID:
1383063
6.

[Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].

de Clercq E, Snoeck R.

Pathol Biol (Paris). 1993 Mar;41(3):230-6. Review. French. No abstract available.

PMID:
7687340
7.

[HEPT and its related compounds as anti-HIV agents].

Miyasaka T, Tanaka H, Baba M.

Nihon Rinsho. 1993 Sep;51 Suppl:200-6. Review. Japanese. No abstract available.

PMID:
7505847
8.

The impact of the M184V substitution on drug resistance and viral fitness.

Wainberg MA.

Expert Rev Anti Infect Ther. 2004 Feb;2(1):147-51. Review.

PMID:
15482179
9.

HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors.

Wainberg MA.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S2-7. Review.

PMID:
14562852
10.

HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring.

D'Aquila RT.

Clin Lab Med. 1994 Jun;14(2):393-422. Review.

PMID:
7523021
11.

Development of nonnucleoside HIV reverse transcriptase inhibitors.

Tucker TJ, Lumma WC, Culberson JC.

Methods Enzymol. 1996;275:440-72. Review. No abstract available.

PMID:
9026654
12.

Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1.

Smith M, Salomon H, Wainberg MA.

Clin Invest Med. 1994 Jun;17(3):226-43. Review.

PMID:
7523016
13.

[Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection].

Salomon HE, Pampuro SE, Gu Z, Montaner JS, Libonatti O, Wainberg MA.

Rev Argent Microbiol. 1995 Oct-Dec;27(4):214-29. Review. Spanish. No abstract available.

PMID:
8850135
14.

Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.

Kilby JM, Saag MS.

Adv Exp Med Biol. 1996;394:291-8. Review. No abstract available.

PMID:
8815693
15.

HIV inhibitors targeted at the reverse transcriptase.

De Clercq E.

AIDS Res Hum Retroviruses. 1992 Feb;8(2):119-34. Review.

PMID:
1371690
16.

Correlation of molecular conformation and activity of reverse transcriptase inhibitors.

Van Roey P, Taylor EW, Chu CK, Schinazi RF.

Ann N Y Acad Sci. 1990;616:29-40. Review. No abstract available.

PMID:
1706572
17.

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Arts EJ, Wainberg MA.

Antimicrob Agents Chemother. 1996 Mar;40(3):527-40. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk